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TECHNICAL ADVANCE Open Access
Comprehensive routine diagnostic
screening to identify predictive mutations,
gene amplifications, and microsatellite
instability in FFPE tumor material
Elisabeth M. P. Steeghs1†, Leonie I. Kroeze1†, Bastiaan B. J. Tops1,2, Leon C. van Kempen3, Arja ter Elst3,
Annemiek W. M. Kastner-van Raaij1, Sandra J. B. Hendriks-Cornelissen1, Mandy J. W. Hermsen1, Erik A. M. Jansen4,
Petra M. Nederlof5, Ed Schuuring3, Marjolijn J. L. Ligtenberg1,4† and Astrid Eijkelenboom1*†
Abstract
Background: Sensitive and reliable molecular diagnostics is needed to guide therapeutic decisions for cancer patients.
Although less material becomes available for testing, genetic markers are rapidly expanding. Simultaneous detection of
predictive markers, including mutations, gene amplifications and MSI, will save valuable material, time and costs.
Methods: Using a single-molecule molecular inversion probe (smMIP)-based targeted next-generation sequencing
(NGS) approach, we developed an NGS panel allowing detection of predictive mutations in 33 genes, gene amplifications
of 13 genes and microsatellite instability (MSI) by the evaluation of 55 microsatellite markers. The panel was designed to
target all clinically relevant single and multiple nucleotide mutations in routinely available lung cancer, colorectal cancer,
melanoma, and gastro-intestinal stromal tumor samples, but is useful for a broader set of tumor types.
Results: The smMIP-based NGS panel was successfully validated and cut-off values were established for reliable gene
amplification analysis (i.e. relative coverage ≥3) and MSI detection (≥30% unstable loci). After validation, 728 routine
diagnostic tumor samples including a broad range of tumor types were sequenced with sufficient sensitivity (2.4% drop-
out), including samples with low DNA input (< 10 ng; 88% successful), low tumor purity (5–10%; 77% successful), and
cytological material (90% successful). 75% of these tumor samples showed ≥1 (likely) pathogenic mutation, including
targetable mutations (e.g. EGFR, BRAF, MET, ERBB2, KIT, PDGFRA). Amplifications were observed in 5.5% of the samples,
comprising clinically relevant amplifications (e.g. MET, ERBB2, FGFR1). 1.5% of the tumor samples were classified as MSI-
high, including both MSI-prone and non-MSI-prone tumors.
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Conclusions: We developed a comprehensive workflow for predictive analysis of diagnostic tumor samples. The smMIP-
based NGS analysis was shown suitable for limited amounts of histological and cytological material. As smMIP technology
allows easy adaptation of panels, this approach can comply with the rapidly expanding molecular markers.
Keywords: Predictive analysis, Next-generation sequencing, Mutation, Gene amplification, Microsatellite instability, FFPE,
Melanoma, GIST, Colorectal carcinoma, Lung cancer
Background
Personalized medicine becomes increasingly important in
cancer treatment. Drugs targeting specific mutated genes
or specific activated pathways are clinically available for sev-
eral indications, e.g. for EGFR-mutated lung cancer [1].
Currently, many more targeted therapies are being evalu-
ated in clinical trials and show promising results either
alone or in combination with other drugs [2]. As molecular
markers are constantly expanding, predictive analysis
should be easily adaptable to future clinical need. In this era
of personalized medicine, next generation sequencing
(NGS) analysis using gene panels is increasingly becoming
a standard diagnostic approach as interrogation of multiple
molecular markers is required with only a limited amount
of (mostly) formalin-fixed, paraffin-embedded (FFPE) tissue
[3]. These markers include a spectrum of genetic alter-
ations, ranging from small base pair alterations (e.g. point
mutations, small deletions, or small insertions) to larger
structural variants (e.g. translocations, amplifications, or de-
letions) affecting genes or large regions of chromosomes.
Besides therapy decision, the presence or absence of spe-
cific genetic alterations can contribute to the differential
diagnosis and provide relevant prognostic and predictive
value [4]. In addition, mismatch repair deficiency, causing
instability of repetitive DNA sequences known as microsa-
tellites, was shown to be predictive for response to immune
checkpoint blockade for a range of tumor types [5].
Sequencing is considered a high resolution approach for
the detection of small genetic alterations. With the intro-
duction of sensitive NGS techniques, mutations can reliably
be detected in a very low number of cells. We have previ-
ously implemented and validated the single molecule Mo-
lecular Inversion Probes (smMIP) approach that includes
molecular tagging to identify PCR duplicates. These dupli-
cate reads are merged into consensus reads, which leads to
the elimination of PCR and sequencing artifacts. In com-
bination with the strand-specific analysis to distinguish
genuine mutations from deamination artefacts, it is possible
to detect point mutations, small deletions, small insertions,
and complex mutations (indels) down to at least 1% mutant
allele frequency, as well as to reliably exclude sequence vari-
ants with a mutant allele frequency > 3% [6]. In addition,
existing gene panels are easily adaptable [6] and thereby
this technology can comply with the growing clinical need.
Taken together, the smMIPs technology allows screening
of multiple therapeutic targets with high sensitivity using
FFPE tissue material in a routine diagnostic setting.
Detection of copy-number variations (CNVs) at specific
genomic locations, e.g. amplification of MET, is frequently
performed by fluorescence in situ hybridization (FISH). In
addition, several genome-wide approaches are available,
including (shallow) whole genome sequencing or (SNP)
array. Interestingly, in the last few years it was shown that
NGS-based approaches using defined gene panels are able
to identify CNVs in parallel to sequence alterations [7–
10]. Recommendations were published to guide the detec-
tion and reporting of copy number gains using gene-panel
NGS data in a routine diagnostic setting [11].
Recent developments, showing clinical benefit of im-
mune checkpoint blockade in microsatellite instability
(MSI) positive tumors, increased the importance of tumor
agnostic MSI detection [5]. MSI is characterized by spon-
taneous gains or losses of nucleotides in small nucleotide
repeat regions (microsatellites) and reflects a state of gen-
omic hypermutability. In diagnostic FFPE tissue, the
microsatellite status is routinely investigated by a penta-
plex PCR investigating five microsatellites [12]. This ana-
lysis was mainly validated in Lynch syndrome associated
tumors, but little data is available regarding the reliability
of this analysis in other tumor types [13, 14]. Studies fo-
cusing on the spectrum of unstable microsatellites across
multiple cancers show different patterns of MSI among
cancer types [15–17]. NGS analyses can be used to study
multiple microsatellite loci in one test [13, 17–21].
Taken together, different molecular techniques (i.e.
NGS, FISH, and pentaplex PCR) are often used for pre-
dictive analyses for cancer therapy. NGS gene panel ana-
lysis allows detection of these genomic aberrations in
one assay, which will potentially save valuable time, ma-
terial and costs. Therefore in the current study we aimed
to develop a single smMIP-based NGS assay, which can
detect sequence alterations, amplifications, and MSI. To
comply with the increased number of therapeutic oppor-
tunities based on molecular aberrations, both in regular
therapeutics and in clinical trial settings, our panel was
designed to allow predictive screening for the four most
requested molecular-screened indications, i.e. lung can-
cer, colorectal cancer, melanoma and gastro-intestinal
stromal tumors (GIST), but is also useful for evaluation
of a broad spectrum of other tumor types as well.
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Molecular markers for initial therapy decisions as well as
markers important for disease progression (i.e. resistance
mechanisms) were included in the panel. In addition, we
validated and implemented the detection of clinically
relevant gene amplifications in compliance with recently
published recommendations [11], and we included the




The Predictive Analysis for THerapy (PATH) panel
should cover all clinically relevant predictive markers for
molecular testing of lung cancer, colorectal cancer, mel-
anoma, and GIST. To select predictive markers that have
a consequence for targeted treatment-decision-making,
clinicians and pharma companies were consulted, as well
as the scientific societies (e.g. Dutch Association of
Chest Physicians (NVALT), melanoma, and GIST-
Consortium), and literature and clinical trial registries
were screened for relevant genomic alterations for the
specified cancer types. A combination of occurrence,
predictive value, and clinical consequences guided the
selection of a sequencing panel encompassing 13 kb
(Table 1, Supplementary Table 1). Consensus of the
panel was obtained with molecular biologists of three
specialized hospitals.
Sample preparation
Samples were prepared as previously described [6]. In
short, gDNA was isolated from FFPE tissue sections
(generally 3 × 20 μm) using 5% Chelex-100 and 400 μg
proteinase K followed by purification using NaAc and
EtOH precipitation. DNA concentrations were measured
using the Qubit Broad Range kit (Q32853; Thermo-
Fisher, Waltham, MA). Previously, we reported correla-
tions between a low DNA concentration, the number of
years between tissue sampling and DNA isolation, and
suboptimal smMIP-based NGS results [6]. However, no
clear thresholds could be defined. As pre-sequencing
analyses are time-consuming, which hampers the turn-
around time of the majority of samples, the smMIP-
based NGS analysis was performed on all samples with-
out preselection based on DNA quality.
Preparation of the smMIP pool
smMIPs for novel targets were designed using the MIP
pipeline as described previously [6, 22]. In brief, for mu-
tational analyses preferentially each region had to be
covered by two independent smMIPs targeting both
strands (double tiling). Hotspots including surrounding
regions or complete exons (including splice sites) in 29
genes were selected for mutational analyses. For gene
amplifications at least 10 smMIPs per gene were used,
which were spread throughout the gene without double
tiling. For some genes the smMIPs that were designed
for mutation detection fulfilled these criteria, whereas
for other genes additional smMIPs were designed (Sup-
plementary Table 1–2). Seven smMIPs for amplification
analysis showed inefficient capture and sequencing of
targeted regions. Therefore these smMIPS were replaced
by newly designed smMIPs on adjusted target regions
(Supplementary Table 2). To provide a sex control,
smMIPs targeting X-chromosomal AMELX and Y-
chromosomal AMELY were added to the panel. During
smMIP design the presence of common SNPs (minor
Table 1 PATH panel
Mutation analysis Amplification analysis MSI

































Steeghs et al. BMC Cancer          (2020) 20:291 Page 3 of 15
allele frequency > 0.2%) under probe sequences was
avoided. If unavoidable, smMIPs were designed to
recognize the variant alleles, resulting in 76 additional
smMIPs. For MSI detection, smMIPs targeting the five
microsatellites of the pentaplex PCR analysis [23] were
included, resulting in a total of 554 smMIPs. In a later
stage, smMIPs for 50 additional microsatellite regions
were designed and added to the sequencing panel (Sup-
plementary Table 3–4).
The designed smMIPs (Integrated DNA Technologies
(IDT), Leuven, Belgium) were pooled in an equimolar
fashion. The smMIP pool was phosphorylated with 1 μL
of T4 polynucleotide kinase (M0201; New England Bio-
labs, Ipswich, MA) per 25 μL of 100 μmol/L smMIPs in
ATP-containing T4 DNA ligase buffer (B0202; New
England Biolabs, Ipswich, MA). Based on the obtained
coverage for each smMIP, the pool was rebalanced by
increasing the concentration of some of the smMIPs.
The molecular ratio between gDNA and smMIPs was
set to 1:3200 based on 100 ng gDNA input.
Automated smMIP library preparation and sequencing
Library preparation was performed as previously de-
scribed [24]. The final purified libraries were denatured
and diluted to a concentration of 1.2 pmol/L. Sequencing
was performed on a NextSeq 500 (Illumina, San Diego,
CA) according to the manufacturer’s instructions (300
cycles Mid-Output or High-Output sequencing kit),
resulting in 2 × 150 bp paired-end reads.
Variant detection
Data analysis was performed as previously described [6,
24]. The first steps of data conversion were done auto-
matically, i.e. BCL-to-FASTQ conversion and demulti-
plexing [24]. Demultiplexed FASTQ files were uploaded
and analyzed in Sequence pilot version 4.4.0 (JSI medical
systems, Ettenheim, Germany) [6], which included re-
moval of PIK3CA and PTEN pseudogene reads from the
alignment and subsequent analysis. After variant calling,
all variants were manually inspected and curated. To im-
prove detection of large deletions resulting in skipping
of MET exon 14, we decreased the percentage of con-
secutive bases that have to match to the reference with-
out a mismatch (30% instead of 50%) and the minimum
total absolute coverage for both directions combined (10
instead of 20). To evaluate detection of large deletions
resulting in skipping of MET exon 14, three artificial
DNA sequences (IDT) were used.
Amplification analysis
An external baseline control series was generated from
ten normal FFPE tissue samples, which were sequenced in
several independent runs. The unique coverage per tumor
sample was normalized using the median sequencing
depth of all amplicons in the sample, an approach adapted
from Budczies et al [7]. This normalized coverage per
gene per sample was divided by the mean coverage of the
gene in the control series. The obtained value includes the
relative unique coverage (or fold change) and can be di-
vided by two to assess the total number of alleles that are
present per genome equivalent. In addition, a significance
score, the z-score, was calculated by dividing the differ-
ence between the normalized coverage of the sample and
the control series by the standard deviation of the control
series. To assess the number of alleles that are present in
the tumor cells only, the relative coverage was corrected
by tumor purity: (relative coverage * 2 – (1 – fraction of
neoplastic cells)*2) / fraction of neoplastic cells [11].
Microsatellite instability detection
mSINGS software was used for the detection of signifi-
cantly altered read length distribution in sequencing
reads covering microsatellite markers, as described by
Salipante et al [20]. This tool is able to perform tumor-
only MSI analysis without the need of a paired normal
sample. In short, baseline reference values were gener-
ated from 20 normal FFPE tissue samples for the 55
microsatellite loci. Microsatellite status of unknown
samples was assessed by comparing repeat length distri-
bution for each locus to the baseline reference value. Per
locus, the total number of alleles with different lengths
was assessed. Repeat lengths were included if their read
count exceeded 5% compared to the read count of the
most frequently observed allele. The number of repeat
lengths was compared to the number of the baseline. If
the counted repeat lengths exceeded [mean number of
alleles + (2 x SD)] the baseline value, a locus was scored
as unstable. Finally, the mSINGS score was assessed by
dividing the number of unstable loci per samples by the
total number of evaluated loci.
OncoScan CNV array
80 ng DNA from FFPE samples was processed according
to the manufacturer’s instructions (ThermoFisher Cat.
No. 902694). Data was visualized and analyzed using
Chromosome Analysis Suite (ChAS) software version 3.2
(ThermoFisher).
Panel requirements
The requirements of the PATH panel were formulated
prior to its validation and implementation, including i)
> 90% of selected regions of interest should be double
tiled, preferably recognizing both strands for hotspot re-
gions. ii) Read depth distribution throughout the panel
should be uniform; the average read depth for > 90% of
the targets relevant for sequencing analysis may vary up
to 1 order of magnitude. iii) The number of sample
drop-outs should be similar or smaller compared to the
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smMIPs cancer hotspot panel [6] and concordant results
should be obtained. iv) For amplification analysis, 5 posi-
tive controls and 10 samples without any amplification
should be correctly classified. v) For MSI detection, a
series of 10 positive and 20 negative control samples
should be correctly annotated.
Results
Panel validation – sequencing analysis
The smMIPs were pooled in an equimolar fashion and
tested on 4 samples of archived FFPE tumor tissue. To
boost coverage of underperforming smMIPs relevant for
sequence analysis, the concentration of 55 smMIPs was
increased (Supplementary Table 2). In addition, 7
smMIPs were replaced by newly designed smMIPs. 10
samples from archived tissue were sequenced using this
rebalanced pool. 91% of relevant regions for mutation
detection were covered by ≥2 smMIPs in both orienta-
tions. Unique read depth obtained from sequence ana-
lysis of these 10 samples resulted in a median coverage
of 506 unique reads per region, representing an equal
number of individually sequenced gDNA molecules. On
average, unique coverage of 96.3% of relevant regions
was within one order of magnitude (Fig. 1a). The cover-
age of 3 regions was lagging behind, i.e. the regions
around ARAF codon 214, ERBB2 exon 18, and ERBB2
exon 21. These regions are relatively GC-rich (GC%
ARAF region: 62%, ERBB2 exon 18: 66%, ERBB2 exon
21: 59%), which might partly explain why these regions
are more difficult to amplify and sequence (Supplemen-
tary Table 5), as previously shown [6]. Since these re-
gions are not frequently mutated, we accepted the lower
coverage of these regions.
Subsequently, 57 tumor samples (NSCLC, colorectal
carcinoma, melanoma, GIST, and a range of tumor types
for which clinical trial options were evaluated (hereafter
referred to as ‘miscellaneous’) were sequenced using this
new pool (Fig. 1b) and compared with our routine diag-
nostics cancer hotspot panel [6]. Parallel analysis showed
a comparable number of drop-outs (n = 5) and a com-
parable coverage for the individual regions (Supplemen-
tary Fig. 1). The 5 drop-out samples could be explained
by poor DNA quality, i.e. four FFPE samples were stored
for > 8 years and for one sample a cytological specimen
with partly degraded cells was used. Noteworthy, an-
other five FFPE samples stored for > 8 years performed
well. 75% (39/52) of the successfully evaluated cases har-
bored ≥1 (potentially) pathogenic mutation (Fig. 1c). 32
mutations were identified by both panels and showed
concordant variant allele frequencies (Fig. 1d). The
PATH panel identified 31 additional (potentially) patho-
genic mutations, which were located in regions that were
not present in the cancer hotspot panel (Fig. 1e).
In addition, we evaluated the detection of MET exon
14 skipping mutations, which can either be point muta-
tions, deletions, or indel mutations that target the splice
donor or acceptor site of exon 14, or the intronic poly-
pyrimidine tract region [25–27]. In the Hs746T cell line,
a c.3082 + 1G > T mutation at the splice donor site of
MET (NM_001127500.2), predicted to result in MET
exon 14 skipping, was successfully detected by the
PATH panel. The panel design includes smMIPs with
large insert size specifically designed to allow amplifica-
tion of large deletions at this locus. Three artificial DNA
sequences containing a 46, 173, or 201 bp deletion af-
fecting the splice acceptor site (based on Frampton et al
[25]) were detected, suggesting that large deletions af-
fecting one of the splice sites could be detected by the
panel in a diagnostic setting. Indeed, after implementa-
tion in routine diagnostics, a splice donor site mutation
was identified in MET intron 14 (c.3082 + 1G > A) as
well as a 66 bp deletion (c.2942-4_3003del) involving the
MET exon 14 splice acceptor site. Based on these results
and the different MET aberrations described [25, 26], we
estimated that all point mutations and > 90% of all dele-
tions that can result in exon 14 skipping can be identi-
fied by gDNA sequencing using the PATH panel.
Panel validation – amplification analysis
An external baseline control series was generated from
ten normal FFPE tissue samples, with stable perform-
ance in multiple runs (Supplementary Fig. 2A). The effi-
cacy of amplification analysis was evaluated in five
positive control samples, which included a high level
amplified EGFR, MET, and ERBB2 (HER2) sample, and a
median and low level amplified ERBB2 sample. For sam-
ple normalization, median sequencing depth over all
amplicons was used, as this is much less affected by high
level amplifications compared to the mean and summed
unique coverage (Supplementary Fig. 2B). All amplifica-
tions in the positive controls were confirmed, as visual-
ized by a high relative coverage and z-score compared to
the other genes in the samples (Fig. 2a). In addition, the
values for the ERBB2 amplified samples were propor-
tional to the results obtained by ERBB2 FISH analysis,
yielding a ‘high’, ‘median’ and ‘low’ value. Moreover, an
additional EGFR amplification was observed in one
ERBB2 positive control, which was confirmed by FISH
analysis (not shown).
For reliable detection of amplifications in routine diag-
nostics, it is highly recommended to establish cut-offs
for amplification detection [11]. The relative coverage of
46 samples from routine diagnostics were therefore
compared to a control series (Fig. 2b, Supplementary
Fig. 3A). Based on visual inspection, a threshold in rela-
tive coverage ≥3.0 was chosen for further validation,
which corresponded to a z-score of > 6.4 (Supplementary
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Fig. 3B). In addition, the lower limit of alleles that need
to be present in the neoplastic cell component to reach the
threshold of relative coverage ≥3.0 can be deduced based
on the tumor purity of a sample (Supplementary Fig. 3C)
[11]. Nine of 46 samples exceeded the threshold for one or
more genes (Fig. 2c). The observed amplifications complied
with clinical specifications and additional molecular find-
ings [28–33]: we detected an EGFR amplification in four
samples (i.e. three EGFR-mutated lung tumors and one
glioblastoma specimen), a BRAF amplification in two sam-
ples (both BRAF-mutated melanoma samples), a PIK3CA
amplification in one sample (EGFR-mutated NSCLC case
Fig. 1 Validation of sequencing analysis. a Average read depth of 96.3% of the targets is within one order of magnitude. For every region
(hotspot or whole exon) the mean coverage was calculated per sample. By dividing the mean coverage per region through the median coverage
in a specific sample, the mean relative coverage for each region was defined. The average of the mean relative coverage per region of 10
samples is plotted. b 57 samples distributed over the indications lung, colon, melanoma, GIST, and miscellaneous (analysis in the context of
evaluating clinical trial options) were sequenced and compared with the current routine diagnostics panel. c Percentage of samples with a
specific number of mutations. d The variant allele frequencies (VAF) of the 32 mutations identified by both the PATH panel and the cancer
hotspot panel. e Mutations detected in the 52 samples successfully sequenced during the validation phase. Dark red indicates mutations
identified with both panels (cancer hotspot panel and PATH panel). Light red indicates additional mutations identified using the PATH panel. ‘2’
indicates two different mutations identified in the same gene. Dark and light purple indicates variants of unknown significance (VUS) identified by
both panels or PATH panel only, respectively
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that showed progression upon tyrosine kinase inhibitor
treatment), a KRAS amplification in one sample (NSCLC
case without any identified mutations), and an ERBB2
(HER2) amplification in one sample (salivary duct carcin-
oma). Amplifications in five samples were confirmed by
OncoScan array analysis (Fig. 2c (green marker),
Supplementary Fig. 4). Copy number gains with a relative
coverage between 2.0 and 3.0 are marked as ‘potentially
amplified’ to allow follow-up analysis in case the gene amp-
lification is clinically relevant for that particular case.
Cross-validation of the amplification analysis and the
threshold in relative coverage was performed on a series
Fig. 2 Validation of detection of amplifications in smMIP-based NGS analysis on gDNA from clinical FFPE specimens. a Relative coverage and z-
scores in 5 positive controls for EGFR, MET and ERBB2 (n = 3: high, medium, and low level amplification) normalized to a normal tissue control
series. Values of all 13 genes relevant for amplification detection (see Supplementary Table 1) are plotted for the five samples. Values were
calculated per gene per sample and sorted by increasing value. The positive control values (one gene per samples) are depicted in green, values
for all other genes (12 per samples) are shown in black. The additional detected EGFR amplification, shown in orange, was confirmed by FISH. b
Grouped relative coverage in a series of 46 clinical tissue samples and 15 normal tissue controls. Values were calculated per gene per sample. c
Relative coverage per gene in the series of 46 clinical samples, with additional clinical/molecular information (details in main text). The cut-off for
validation (relative coverage ≥3.0) is shown by an orange line. Potential amplifications in green were validated by OncoScan array analysis (the
others were not analyzed by OncoScan array). d Three positive control samples were diluted in gDNA isolated from normal tissue. Relative
coverage (y-axis) and z-scores (above bars) compared with a normal tissue control series are shown. On the x-axis the dilution based on gDNA
concentration is shown. EGFR positive control: unknown tumor purity. ERBB2 high positive control: 70% tumor cells. ERBB2 low positive control:
50% tumor cells
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of samples containing amplifications of FGFR1, KRAS,
MDM2, MET, or PDGFRA (Supplementary Table 6).
The amplifications that were not detected by the PATH
panel analysis were below the limit of detection due to a
low tumor purity, or subclonal event as determined by
FISH (Supplementary Table 6). A dilution series of three
positive controls diluted in gDNA isolated from normal
tissue further demonstrated the importance of both
tumor purity and level of amplification for the sensitivity
of the smMIP-based NGS analysis (Fig. 2d, Supplemen-
tary Table 6). High level amplified EGFR and ERBB2
samples were detected up to 16 and 4 times dilution, re-
spectively. However, the ERBB2 amplification in the me-
dian amplified sample was only detectable in the
undiluted sample. Taken together, limitations in sensitiv-
ity of the smMIP-based NGS analysis in samples with a
low tumor purity and/or low level amplifications need to
be taken into account. To specify these limitations, the
number of required gene copies that can be reliably de-
tected by the smMIP-based NGS analysis given the
tumor purity should be documented.
Finally, the effect of the number of analyzed gDNA
molecules on the amplification analysis was studied. In
two diluted normal tissue specimens, the amount of
gDNA did not affect the relative coverage of the 13
genes (Supplementary Fig. 5A). In addition, samples
from the validation series were grouped in low (median
amplicon coverage < 25 gDNA molecules) or high (≥25
gDNA molecules) coverage (i.e. 25 gDNA molecules is
set as lower limit of detection for variant analysis [6]).
The group with the low unique coverage showed more
outliers (Supplementary Fig. 5B), which is most likely
due to technical variation due to suboptimal gDNA
quality and warrants careful consideration to prevent
false positive calls.
In conclusion, the PATH panel can be used to detect gene
amplifications, which are considered reliable if they have a
relative coverage ≥3, an amplified signal clearly above the
noise based on visual inspection of all genes and in all dupli-
cate or triplicate analyses, and if the median unique cover-
age per amplicon is > 25 unique gDNA molecules.
Panel validation - MSI detection
For MSI analyses, a total of 63 microsatellite repeats
were selected that were recurrently unstable in a range
of MSI unstable tumor types [15, 16]. After initial test-
ing, 55 markers passed the minimal requirements, as
also specified by the mSINGS software. To determine
the sensitivity of the markers, we analyzed the microsat-
ellite status of 20 normal tissue samples, 3 microsatellite
stable (MSS) tumor samples, and 10 MSI-high tumor
samples (i.e. colorectal, endometrial, prostate, and saliv-
ary duct carcinomas) as assessed by Genescan analysis of
a pentaplex PCR [23] and/or immunohistochemistry
(IHC) of the mismatch repair genes. mSINGS software
detected a significantly different read length in 22–87%
of microsatellite markers for the MSI-high samples. Nor-
mal samples and MSS tumor samples showed 0–9% un-
stable loci (Fig. 3a, c). When applying the previously
published cut-off of 20% unstable loci, a 100% sensitivity
and specificity was reached [20]. The sample that scored
the lowest fraction of unstable loci (22 and 27% in dupli-
cate analysis) was an MSH6 deficient prostate tumor,
which showed a more subtle shift in the pentaplex PCR
analysis compared to other positive controls (Supple-
mentary Fig. 6). In three positive control samples (two
endometrial tumors and the MSH6-deficient prostate
carcinoma) none of the microsatellites included in the
pentaplex PCR assay was classified as unstable by the
smMIP-based NGS analysis, suggesting the sensitivity
for these individual loci is lower than the pentaplex PCR
due to the objective cut-off (mean number of alleles + (2
x SD)). Nevertheless, the cut-off of 20% unstable loci
was also reached in these three samples due to instability
of other loci, demonstrating the strength of multiple
microsatellite makers.
The stability of the assay was examined by the evalu-
ation of 5 MSI-high positive controls (2 colorectal car-
cinoma, 2 endometrial carcinoma, and 1 prostate cancer
sample) in two independent sequencing runs. Reprodu-
cible results were obtained (Supplementary Fig. 7A). To
challenge the threshold of 20% unstable loci, 3 positive
control samples were diluted to mimic decreasing tumor
load. Sample 1 harbored a high number of unstable loci
and hence MSI was detected up to a neoplastic cell pur-
ity of 12.5% (Supplementary Fig. 7B). However, the frac-
tion of unstable loci was lower in sample 2 and 3 and
consequently MSI could not be detected below 35 and
30% neoplastic cell purity, respectively. These results
show the importance of both the percentage of tumor
cells and the fraction of unstable loci for the sensitivity
of the MSI analysis. Based on these results, we decided
to use a cut-off of ≥30% neoplastic cell purity to reliably
report an MSS results.
Finally, the MSI analysis was evaluated in 100 samples
for routine diagnostics. Addition of MSI smMIPs to the
PATH panel resulted in near identical coverage of all
targeted regions (Supplementary Fig. 7C) and did not
affect the above described variant and amplification de-
tection (data not shown). Besides the positive controls,
three diagnostic samples (tumor purity > 80%) exceeded
the threshold of 20% unstable loci (56, 25, 20%), which
all three appeared to be lung cancer samples (Fig. 3b, d).
IHC (loss of MLH1 and PMS2) and pentaplex PCR ana-
lysis confirmed MSI in the sample with 56% unstable
loci (Supplementary Fig. 7D). In the sample with 25%
unstable loci (25 and 24% in duplicate analysis) subtle
changes were observed in the PCR pentaplex analysis.
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No material was available for IHC analysis. For the third
sample (19 and 21% unstable loci in duplicate analysis),
none of the PCR pentaplex markers showed instability,
which was in agreement with stability of these same loci
in the smMIP-based NGS analysis. The IHC analysis did
not generate conclusive results for PMS2 and MLH1.
Fig. 3 Validation of MSI detection in smMIP-based NGS analysis on gDNA from clinical FFPE specimens. a The fraction of microsatellite loci that
showed an MSI event is depicted for MSI tumor samples, MSS tumor samples, and normal tissue samples. b The fraction of microsatellite loci that
showed an MSI event is depicted for 100 diagnostic samples and 5 positive control samples. c Landscape of MSI events in the different
microsatellite loci of the samples that are shown in panel A. Each column represent a tumor sample. Each row represents a microsatellite locus.
Colored (red) bars represent unstable loci, white bars represent microsatellite stable loci, and grey bars represent microsatellite loci which could
not be analyzed due to poor quality. The top row shows which sample is depicted: positive control (grey), microsatellite stable tumor sample
(black), or a normal tissue sample (light blue). The bottoms row indicates whether the fraction of unstable loci exceeds 20% (red) or is below 20%
(white). On the left of the figure the location of the microsatellite loci is depicted. Loci that are shown in blue represent the pentaplex PCR
markers. d Landscape of MSI events in the different microsatellite loci of the samples that are shown in panel B. Each column represent a tumor
sample. Each row represents a microsatellite locus. Colored (red) bars represent unstable loci, white bars represent stable loci, and a grey bar
means that the locus could not be analyzed. The top row shows which sample is depicted: positive control (grey), an MSI sample that is
confirmed by another technique (green), a potential MSI sample that could not be confirmed by another technique (blue), or microsatellite stable
diagnostic sample (black). The bottoms row indicates whether the fraction of unstable loci exceeds 20% (red) or is below 20% (white)
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However, the markers for MSI evaluation by IHC and PCR
pentaplex analysis were validated on Lynch syndrome asso-
ciated tumors. Little data is available regarding the reliabil-
ity of the IHC and PCR pentaplex analysis in lung cancer
[14, 17, 20, 34–37]. Therefore, it remains elusive whether
this sample should be considered as MSI-high.
Taken together, these observations prompted us to use a
threshold of 30% unstable microsatellites to classify a sam-
ple as MSI-high. Samples that show < 15% unstable micro-
satellite loci are classified as MSS. For samples with 15–
30% unstable microsatellites IHC of mismatch repair pro-
teins and pentaplex PCR is used to clarify the MSI status.
Analysis in routine diagnostics
As all formulated requirements of the PATH panel were
realized, the PATH panel (Table 1) was implemented as
routine diagnostic procedure for predictive analyses for
cancer therapy within the Radboudumc. In 2018, 745
routinely available diagnostic samples (35% lung cancer,
17% melanoma, 8% colorectal carcinoma, 3% GIST, and
37% miscellaneous tumors (a range of tumor types that
is evaluated for clinical trial options)) were sequenced
for variant detection and gene amplification (Supple-
mentary Table 7). These samples were either analyzed in
the context of first line treatment selection or detection
of therapy resistance. MSI markers were added in a later
stage and therefore MSI analysis was performed only in
a subset of these samples (n = 478). In 18 tumor samples
sequencing analysis was not successful due to low quan-
tity or poor quality of the DNA (2.4% sample dropout;
Supplementary Table 7–8). In addition, MSI could not
be excluded by the smMIP panel in 53 samples due to
too low tumor purity (< 30%). 728 routine diagnostic
tumor samples were sequenced with sufficient sensitivity
(i.e. sufficient reads for reliable variant detection [11]),
including samples with a low amount of DNA (< 10 ng;
28/32 samples successful), low tumor purity (5–10%; 10/
13 samples successful), and cytological samples (56/62
samples successful). Both DNA quantity and quality in-
fluence the quality of the sequence analysis (Supplemen-
tary Table 8) and consequently, the minimum required
DNA input amount will vary per sample. Therefore, no
minimal input requirements were determined and all
samples were subjected to smMIP-based NGS analysis.
The PATH panel showed its capability to detect splice
site mutations (e.g. MET: c.3082 + 1G >A), large deletions
(e.g. MET:c.2942-4_3003del), large insertions (e.g. KIT:
c.1721_1768dup), and complex deletion-insertion muta-
tions (e.g. KIT: c.1924_1936delinsGAAGTCCTGAGTC;
Supplementary Table 7). In total, 788 (likely) pathogenic
mutations, and 94 variants of unknown significance were
detected. Variant allele frequencies ranged from 2 to
100%. 75% (547/728) of the patients harbored ≥1 (likely)
pathogenic mutations, including genes suitable for
targeted treatment options (e.g. EGFR, BRAF, MET,
ERBB2, KIT, PDGFRA). Mutations in KRAS, NRAS, HRAS,
BRAF, EGFR, ERBB2, MET, KIT, and PDGFRA were
mostly mutually exclusive (Fig. 4, Supplementary Fig. 8).
Mutations occurred in tumor types as expected: KRAS
mutations were mainly observed in colorectal carcinoma
(43%) [38] and lung cancer (22%) [1]; melanoma patients
showed a high frequency of BRAF (56%) and NRAS (20%)
mutations [39–41]; EGFR (12%), ERBB2 (1%), and MET
(1%) mutations could be mainly attributed to lung cancer
samples [1]; almost all samples suspected of GIST showed
a mutation (91%) in KIT (68%) or PDGFRA (23%) [42]. In
the remaining tumor types, 57% of the samples harbored a
(likely) pathogenic mutation and/or amplification, includ-
ing amplifications of ERBB2 and EGFR, and mutations in
BRAF and POLE. In general, TP53 was the most fre-
quently mutated gene: 1 or 2 TP53 mutations were ob-
served in 46% (334/728) of the tumor samples [43].
Amplification analysis showed 44 gene amplifications in
5.5% (40/728) of the evaluated samples (Supplementary
Table 7). Amplification of MDM2 was detected most fre-
quently (1.4%; 3 lung cancer, 1 melanoma, 2 liposarcoma,
2 urothelial carcinoma samples), which is reported to be
associated with hyperprogressive disease after immuno-
therapy treatment [44]. Hence, this finding might contrib-
ute to the therapy decision. In addition, potential
targetable amplifications were detected, i.e. high level am-
plifications of ERBB2 [45–47] (colorectal carcinoma, saliv-
ary duct carcinoma, prostate cancer, ovarian cancer),
MET [48, 49] (lung cancer, esophageal carcinoma), and
FGFR1 [50] (lung cancer, colorectal carcinoma).
The PATH panel detected MSI in 7 of the 478 (1.4%)
analyzed tumor samples, including three MSI-prone tu-
mors (i.e. 2 of 50 colorectal cancer, 1 of 6 endometrial
cancer), and four non-MSI-prone tumors (i.e. 1 lung
cancer, 1 prostate cancer, 1 salivary duct carcinoma, and
1 tumor of unknown primary origin; Supplementary
Table 7). The number of unstable loci ranged from 41 to
76% and thereby all these tumors were classified as MSI-
high tumors. Given the low frequency of MSI-high colo-
rectal tumors, results were matched with available mis-
match repair deficiency data. Concordant with the
smMIP-based NGS result, none of the 23 tested colorectal
tumors showed mismatch repair deficiency by immuno-
histochemical staining of MLH1, PMS2, MSH2 and
MSH6 (Supplementary Table 7). In addition, a supple-
mentary set (n = 13) of mismatch repair deficient colorec-
tal carcinomas as determined by IHC, was analyzed,
confirming the assay sensitivity. All samples showed >
30% unstable loci and thus would have been classified as
an MSI-high tumor by sequence analysis with the PATH
panel (Supplementary Fig. 9). Taken together, identifica-
tion of MSI in non-MSI-prone tumors shows the strength
of combination analyses by one NGS panel. As MSI is the
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first tumor-agnostic FDA-approved genetic biomarker
that gives access to therapy, identification of MSI is of im-
portance for any cancer type [5, 51].
Discussion
In the current study, a smMIP-based NGS approach was
validated, which aimed at concurrent detection of genomic
mutations, amplifications, and MSI in small amounts of
histological tumor tissue or cytological material represent-
ing routinely available tumor samples. We provide detailed
information on the validation of the procedure for predict-
ive testing in current clinical practice and show that it is
feasible to reliably analyze different types of genomic aber-
rations using a small smMIP-based NGS panel on diagnos-
tic materials. Based on this sensitive and reliable molecular
diagnostic analysis, cancer patients can be stratified for tar-
geted therapies and immunotherapy regarding currently
available drugs. The combined analysis of different types of
genomic aberrations within one analysis saves valuable
time, material, and costs. In addition, a broad predictive
analysis allows identification of genomic aberrations that
are rarely considered by clinicians, e.g. MSI in a non-MSI-
prone tumor or a KIT mutation in melanoma, which might
be beneficial for treatment options [5, 51, 52].
Fig. 4 Mutational landscape of 729 tumor samples, which were analyzed with the PATH panel in routine diagnostics. (Likely) pathogenic
mutations, variants of unknown significance, amplifications, and MSI status are depicted in the figure. Tumor samples are sorted on genetic
alterations, followed by tumor type, and MSI status. Each column represents a tumor sample. Each row represents a genetic alterations (i.e.
mutation (light red, red, or dark red), CNV (cyan), or MSI (light red). A colored bar represents a genetic alterations, a white bar represents no
alteration, and a grey bar represents not analyzed. The top row shows the tumor types of the analyzed samples: lung cancer (dark blue),
colorectal cancer (light blue), melanoma (dark green), GIST (light green), or miscellaneous (black)
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Previously, simultaneous detection of mutations with
either amplifications or MSI using targeted NGS was de-
scribed [10, 13, 19, 53–55]. To our knowledge this is the
first small smMIP-based NGS panel that allows concur-
rent analysis of mutations, amplifications, and MSI by
numerous microsatellite loci. Although whole-genome
sequencing offers the most comprehensive analysis, the
lack of fresh frozen material, high costs and low
amounts of tissues/neoplastic cells hinder its use in rou-
tine diagnostics. Targeted NGS approaches on the other
hand offer lower costs, can yield higher coverage for re-
gions of interest, offer a fast turnaround time, and allow
analysis of FFPE specimens with suboptimal gDNA qual-
ity. Our panel uses a PCR-based target enrichment
method, which is suitable for small gene panels and can
handle low (< 10 ng) gDNA input. Upscaling our routine
diagnostic panel from the previously published Cancer
Hotspot Panel (247 smMIPs [6]) to the PATH panel
(663 smMIPs) did not affect sensitivity. In addition, the
smMIP panel can be easily adapted by adding smMIPs
that target new regions to an already optimized smMIP
pool [6], which is an advance in the constantly changing
field of personalized medicines and molecular markers,
as was demonstrated by the addition of microsatellite
markers. Nevertheless, the PATH panel does not prevent
additional predictive analyses. Immunohistochemistry of
PD-L1, ALK and ROS1, or mRNA based analysis to de-
tect relevant fusion genes involving ALK, ROS1, RET, or
NTRK genes cannot be replaced by the PATH panel
[56]. In addition, tumor mutational burden, associated
with a favorable response to immune checkpoint inhibi-
tors [57, 58] cannot be performed by a small NGS panel.
Although large (commercial) NGS panels (> 1Mb) can
be used for this analysis instead of whole-genome se-
quencing or whole-exome sequencing, these panels are
generally more expensive, time consuming (due to the
complexity of the analysis and interpretation of results),
and not appropriate for all diagnostic requests.
The PATH panel was designed to cover most targetable
mutations and amplifications for lung cancer, colorectal
cancer, melanoma, and GIST for first line treatment op-
tions, as well in the setting of therapy resistance (e.g.
EGFR, ALK and KIT gatekeeper mutations). In addition,
the panel can be used to evaluate possible treatment op-
tions for other cancer types in a named or compassionate
use program. The 729 diagnostic tumor samples that were
evaluated with the smMIP panel showed 788 (likely)
pathogenic mutations, including mutations that give ac-
cess to targeted treatment options (e.g. mutations in
EGFR, BRAF, MET, ERBB2, KIT, PDGFRA). Several large
deletions and insertions in MET and KIT were found.
Moreover, clinically relevant amplifications were identi-
fied, including targetable amplifications (i.e. MET, ERBB2,
FGFR1) and amplifications (MDM2) associated with
hyperprogressive disease upon immunotherapy treatment
[33, 44–46, 48, 50, 59]. Targetable aberrations were not only
detected in lung cancer, colorectal cancer, melanoma and
GIST, but also in the other cancer types. Lastly, MSI was
observed in both MSI-prone and non-MSI-prone tumor
samples, which predicts response to immunotherapy [5, 51].
These results show that with the PATH panel a broad
spectrum of actionable genetic alterations can be evaluated.
During validation, cut-offs for gene amplifications and
MSI analysis were established. In addition, we have identi-
fied pitfalls of these analyses. Amplification analysis by
NGS relies on sequencing coverage possibly combined
with VAFs of germline polymorphisms (SNPs) [11]. We
based our analysis on sequencing coverage. Before cover-
age outliers can be detected, a suitable normalization
method has to be applied. The median coverage was
shown to be a convenient normalization method, whereas
the mean and summed coverage appeared less suitable.
To detect coverage outliers, coverage in the sample can be
compared to normal samples in the same sequencing run
or an external reference pool [10, 60–62]. This latter one
saves valuable costs and time (due to lack of availability of
a normal sample for every tumor sample) and was shown
to generate reliable results. Detection of outliers can be
achieved by determining a threshold [54, 63, 64], calculat-
ing a p-value [7, 61], or bootstrap based estimation of the
confidence intervals [65]. We chose for the threshold
method and validated a relative coverage ≥3.0. This
method allows quantification of amplifications by dedu-
cing the number of alleles in the tumor cells from the rela-
tive coverage and tumor purity of the sample [11].
Accordingly the clinical relevance of amplifications can be
established (i.e. low or high number amplification). In
addition, the number of gene copies that needs to be
present to be quantifiable by the NGS analysis can be de-
duced and should be considered to be included in the
diagnostic report to specify restrictions of NGS-based de-
tection of copy number gains [11]. Although these deduc-
tions depend on the estimated tumor purity, which is
error-prone, the VAF of somatic variants can be used to
support this estimation. If a low sensitivity is obtained or
low-level amplifications are of interest, one could consider
FISH analysis to detect a specific amplification or OncoS-
can array to comprehensively analyze copy number varia-
tions. Despite that these analyses are more sensitive to
exclude the presence of amplifications, especially in sam-
ples with limited tumor load and to detect low level ampli-
fications or amplifications in a subset of tumor cells with
clusters, the smMIP-based NGS based analysis offers a
cost-effective multiplex approach.
Like amplification analysis, MSI analysis was estab-
lished without the need for a paired normal sample. The
five markers that are routinely studied by the pentaplex
PCR are mainly validated in Lynch syndrome associated
Steeghs et al. BMC Cancer          (2020) 20:291 Page 12 of 15
tumors. This approach is not necessarily applicable to
NGS based analysis on different tumor types. With re-
spect to the tumor type, different microsatellites might
be affected. Indeed, studies focusing on the spectrum of
unstable microsatellites across multiple cancer types
showed different patterns of MSI [15–17]. The NGS
based methodology also differs from the fragment length
analysis based read out. In the smMIP-based NGS panel
55 microsatellite repeats were included that were re-
ported unstable across multiple cancer types in NGS
based analysis [15, 16]. By increasing the number of
microsatellites that are evaluated, the smMIP-based
NGS panel may be more sensitive for a broad range of
tumor types compared to the traditional pentaplex PCR.
If new predictive microsatellite loci are identified in fu-
ture studies, smMIPs that target these microsatellite re-
gions can be added to the smMIP pool. Tumor purity
also contributes to the sensitivity of the assay. We deter-
mined a cut-off of at least 30% tumor cells to reliably ex-
clude MSI and a fraction of unstable loci of over 30% to
classify a sample as MSI. The relative low number of
MSI-high samples in colorectal carcinoma urged add-
itional validation which confirmed the assay sensitivity.
The low frequency of MSI in the colorectal carcinoma
samples in the diagnostic cohort, is in line with a low
frequency of MSI-high tumors among metastasized colo-
rectal cancer cases [66].
Conclusion
More genomic information can be extracted from tumor
samples than ever before, but less material is available
for testing. In the current study, we show that reliable,
sensitive, and simultaneous detection of mutations, gene
amplifications, and MSI can be achieved in routinely
available diagnostic tumor samples using an integrated
smMIP-based NGS approach, which was designed in
close collaboration with clinicians and molecular biolo-
gists of several specialized centers. This single smMIP-
based NGS test reduces the number of analyses that are
typically performed on tumor samples, uses only limited
amount of material, and thereby simplifies the workflow
for molecular cancer diagnostics. Moreover, the panel al-
lows easy adaptation and can thereby comply with the
rapidly expanding molecular markers.
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